Short answer
Axogen, Inc. (AXGN) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Axogen posted a corporate presentation on November 9, 2026 for use in analyst and investor discussions.
Axogen, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Axogen posted a corporate presentation on November 9, 2026 for use in analyst and investor discussions
- Presentation available through Axogen’s investor-relations website and Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Corporate presentation outlines a prostate nerve reconstruction launch using Avance, expanding Axogen beyond its existing peripheral-nerve markets
- Estimated addressable market: approximately 110,000 annual cases and $754 million TAM at approximately $7,000 weighted ASP
- Clinical experience includes more than 220 reconstructed patients, with approximately 80% exceeding expected erectile-function recovery
- More than 95% of reported patients regained continence, supporting potential quality-of-life and surgeon-adoption benefits
- Key execution risks: clinical validation, regulatory processes, reimbursement, market access and surgeon adoption
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axogen, Inc. 8-K filings
Get the next AXGN 8-K as it lands
Follow AXGN for push alerts, or ask the research agent what this filing means.